Table 3.
Risk factors associated with discontinuation due to secondary nonresponse among patients treated with monoclonal antibodies (MAB) and pegylated antibody (PEG).
| HR | 95% CI | |
|---|---|---|
| Monoclonal antibodies (IFX and ADL) n = 138 | ||
| Baseline RF >203 IU/mL | 3.63 | 2.15–6.14 |
| No MTX use | 0.73 | 0.42–1.30 |
| Baseline DAS28 | 1.02 | 0.86–1.20 |
| Age | 1.01 | 0.99–1.02 |
| Female sex | 1.41 | 0.69–2.87 |
| Pegylated antibody (CZP) n = 32 | ||
| Baseline RF >203 IU/mL | 0.46 | 0.06–3.32 |
| No MTX use | 3.41 | 0.56–20.78 |
| Baseline DAS28 | 1.35 | 0.59–3.06 |
| Age | 0.94 | 0.89–1.01 |
| Female sex | 3.42 | 0.72–16.22 |
HR, hazard ratio; IFX, infliximab; ADL, adalimumab; MTX, methotrexate; DAS28, 28-joint Disease Activity Score; CZP, certolizumab pegol.